DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference
10 6월 2014 - 8:30PM
Marketwired
DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual
American Diabetes Association Conference
MINNEAPOLIS, MINNESOTA--(Marketwired - Jun 10, 2014) - DiaMedica
Inc. (TSX-VENTURE:DMA), a clinical stage biopharmaceutical company
focused on the treatment of diabetes and its complications, today
announced it will be presenting a poster titled "Safety,
Tolerability, Pharmacokinetics and Pharmacodynamics of Recombinant
Human Tissue Kallikrein-1 (DM199) in Healthy Volunteers and
Patients with Type 2 Diabetes Mellitus" at the American Diabetes
Association's (ADA) 74th Scientific Sessions, being held on June
13-17 in San Francisco, California.
The poster has been assigned the presentation number 0977-P in
category 01-D Clinical Therapeutics/New Technology -
Non-Insulin Injectables. The poster is scheduled to be
presented on Saturday, June 14th, 2014 from 11:30-1:30 pm.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical
stage biopharmaceutical company focused on the discovery and
development of novel therapies to treat diabetes and the
complications associated with diabetes. DiaMedica's lead clinical
stage product, DM199, is a recombinant human protein known as
rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel
monoclonal antibody, DM204 for the treatment of Type 2 diabetes,
which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada
under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
DiaMedica Inc.John SavageChief Financial
Officer763-208-6434info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024